New drug SCTB14 takes on standard immunotherapy in lung cancer showdown

NCT ID NCT07362459

Recruiting now Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares a new experimental drug, SCTB14, to the standard immunotherapy pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels (TPS ≥10%). About 246 participants will receive either SCTB14 or pembrolizumab every 3 weeks. The main goal is to see if SCTB14 can delay cancer growth better than the current standard.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SCTB14 (an experimental immunotherapy drug given by IV every 3 weeks)
What this could lead to: If SCTB14 works better than pembrolizumab, it could offer a new first-line immunotherapy option for people with advanced lung cancer.
What could go wrong: This is an early-stage comparison; SCTB14 may not prove superior or could have unexpected side effects. The trial is still recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CARCINOMA NSCLC

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.